drugset / Trial / NCT06545929

Study of Sunobinop on Craving in Alcohol Use Disorder

NCT06545929

Phase 2 Completed 40 enrolled Knoa Pharma LLC Imbrium Therapeutics · collab
RandomizedParallel-groupTriple-blindTreatment

Summary

The purpose of this study is to evaluate the efficacy of sunobinop compared to placebo on alcohol craving in subjects with moderate to severe alcohol use disorder and these subjects are seeking treatment.

Timeline

Start
2025-01-28
Primary completion
2025-07-14
Completion
2025-07-14

Drugs

EvaluationDrugModalityDoseRoute
Subject Sunobinop Small molecule Oral